Conventional histological methods were used to screen for myelinopathy. Samples from representative levels in the neuraxis were examined, including myelinated regions of the brain stem. Special stains for myelin were used in cases showing spongioform change.
Biochemistry, Royal Hospital for Sick Children, Edinburgh EH9 ILJ; and the §MRC Reproductive Biology Unit, Edinburgh EHI 2Q W, UK SUMMARY At least four out of 97 low birth weight (< 1750 g) newborn infants who had received only limited skin disinfection with 3 % hexachlorophane (HCP) emulsion developed spongioform myelinopathy in association with detectable amounts of HCP in their brains. These four cases were found in a post-mortem survey of 20 out of the 27 infants who died. Another nine of these infants had detectable amounts of HCP in the brain but no myelinopathy. It is at present not possible to define a 'safe' level of exposure to 3 % HCP emulsion for small preterm infants in the first 2 weeks of life.
Hexachlorophane (HCP) is now subject to prescribing control but is available for use under medical supervision and widely employed for antisepsis in hospitals. It has played an important part in reducing neonatal staphylococcal infection, which can be such a serious problem in maternity nurseries,' but there is evidence that it can cause spongioform myelinopathy. Almost all the reported cases have been in infants of low birth weight.2-4 A 'safe' level of exposure for infants has not been established.5
For the two-year period 1973-4 we continued to use HCP in the care of newborn infants, reducing the extent of application. We report here, for this two-year period, the relationship between the HCP concentration in brain tissue and spongioform myelinopathy in small preterm infants who died.
Patients and methods
Over the period of the survey there were 8709 live births. Among them were 97 infants of birth weight less than 1750 g who survived one day or more. Twenty-seven out of the 97 died and 20 of these were examined postmortem. All Radioactivity in the residues analysed by GC-MS was measured by liquid scintillation counting. Percentage recovery was consistent in the three major batches of analyses, the means (+ SEM) being 66-7 + 4-8% (n = 20), 66 8 + 3-7%o (n = 20), and 68-7 ± 2-5 % (n = 12). To check the sensitivity and specificity of the method brain samples from six 'cot death' infants who had no recent exposure to topical HCP were analysed without added radioactive HCP. No HCP was detected in any of these samples.
Results

HISTOLOGICAL FINDINGS
Spongioform myelinopathy of similar distribution, although varying in degree, was found in four out of the 20 infants examined (Table) . Spongioform change was found throughout the myelinated regions, being particularly severe in medial structures of the medulla and the tegmental part of the pons. In contrast, white matter areas such as the corticospinal pathways, which are non-myelinated in preterm babies, were free of vacuolation ( Figure) . In paraffin sections vacuoles were mainly 10-30,tm Table. Apart from low birth weight, the respiratory distress syndrome, apnoea requiring assisted ventilation, and coagulation defects were common features. These are common features in low birth weight preterm infants who die in the neonatal period, and in respect of them there was no significant difference between infants with or without spongioform myelinopathy or between infants with or without HCP in brain tissue. Only one of the four infants with spongioform myelinopathy had evidence of asphyxia at birth: two convulsed, but one of those did so within a few hours of delivery in association with the early development of apnoeic attacks. Among the preterm infants examined there was no notable difference in gestational age between the three major groups (Table) defined by the presence of hexachlorophane or myelinopathy, or both.
The main distinction between the three groups was in the length of survival. Despite the absence of clinical neurological abnormalities the evidence of absorption and of possible pathological effect indicates the need for great caution in the use of HCP emulsion on the skin of newborn infants, especially abraded skin. '4 Seemingly it is in the early days of life, probably during the first two weeks, that a small preterm infant is most vulnerable, especially when jaundiced. This may be related to the character of the skin at this time and to immaturity of the hepatic glucuronyl transferases and excretion mechanisms. It would therefore appear unwise to use 3 % HCP emulsion on the skin of infants weighing under 1750 g during the first two weeks of life at least. The evidence does not seem to justify a total ban on the use of HCP, particularly in view of its undoubted value in preventing neonatal staphylococcal infection, which has recently been confirmed by a 'controlled' trial in the population we have studied (Tonkin, personal communication). There is need for further information on the possibly less toxic effects of HCP in dusting powder, another common form of topical application.
